Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A framework is presented for equitable and effective microbiome research partnerships between African researchers, international partners, healthcare professionals, policymakers and stakeholders.
The National Cancer Institute’s Office of Data Sharing is implementing a framework for data sharing and public access policies, which will empower innovation and maximize therapeutic benefits for the cancer community.
By leveraging paired microbiome and human gene expression data from pediatric patients who underwent hematopoietic cell transplantation, distinct lung–immune system–microorganism interactions were identified as important drivers of fatal lung injury.
Sustained safety outcomes were seen at 2-year follow-up after induced pluripotent stem cell-derived mesenchymal stromal cell infusion in 15 individuals with steroid-resistant acute graft-versus-host disease.
In the COMPASSION-04 trial, first-line treatment with a bispecific antibody targeting CTLA-4 and PD-1 and chemotherapy in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma resulted in clinical responses with a manageable safety profile.
Next-generation liquid biopsy technologies that target the detection of cell-free DNA with fragments of circulating tumor DNA could be a game-changer in early cancer detection, but their adoption requires further clinical testing and consideration of harm.
Multiomics and spatial mapping of tumor samples derived from a real-world cohort of patients with advanced renal cell carcinoma, as well as integration of transcriptomics and human leukocyte antigen genotyping data, provides a machine learning-derived signature of response to immune checkpoint blockade.
Multiomic factor analysis of blood multiomic data, including single-cell transcriptomics, for individuals with either acute or chronic coronary syndrome identifies immune cell signatures that correlate with treatment outcomes.
An early-phase trial suggests safety and improvements in vision after treatment with the CRISPR-based therapy EDIT-101, providing proof of concept for in vivo retinal gene editing.
Externally applied electrical stimulation over the cervical spinal cord improves arm and hand functions in people with chronic tetraplegia due to spinal cord injury.
A neural epigenetic signature detectable via plasma analyses is prognostic in patients with glioblastoma, resembling an oligodendrocyte-progenitor- and neuronal-progenitor-cell-like state and showing increased neuro-to-glioma synapse formation.
A deep learning model is used to classify central nervous system tumors based on their DNA methylation profile directly from histopathology, and showed high accuracy in a large set of external validation cohorts, potentially informing downstream treatment.
Multi-omics profiling of the blood and heart of two human decedents receiving pig heart xenografts, including single-cell studies, reveals early immune responses and perioperative cardiac xenograft dysfunction in one of the two decedents, which may be due to mismatched heart size and/or insufficient immunosuppression.
In a randomized trial testing two types of catheter ablation treatments for persistent atrial fibrillation, a large-tip, dual pulsed field and radiofrequency catheter with a large footprint was non-inferior to a conventional radiofrequency catheter.
Data from a large randomized trial show that a personalized diet can improve cardiometabolic health, providing support for a ‘food as medicine’ concept that, although centuries old, still lacks robust evidence.